Mitsubishi UFJ Capital Research
Investment Thesis
Mitsubishi UFJ Capital ("MUCAP") was founded in 1974 as one of Japan's very first venture capital firms, and serves today as the venture capital arm of Mitsubishi UFJ Financial Group (MUFG), Japan's leading financial group. Their mission has remained unchanged since founding: share the aspirations of entrepreneurs, establish trust as a capital partner, and assist throughout all stages of growth — from seed to IPO.
MUCAP supports "the realization of start-ups' dreams" by investing in innovative business ideas that anticipate societal needs. They actively engage in commercializing research results from universities and academic institutions, and are willing to back start-ups in fields where commercialization takes a long time, including life sciences and new industrial fields. Their role goes beyond capital: they help forge business partnerships with large corporations to expand sales channels, provide organizational advice with an eye toward IPO, and leverage the full MUFG financial group's resources for portfolio companies.
Sector Focus
MUCAP is deliberately sector-agnostic and invests across a broad range of industries:
- Life sciences, biopharmaceuticals, and regenerative medicine (with a dedicated internal Life Science Department)
- ICT, artificial intelligence (AI), and Internet of Things (IoT)
- SaaS, enterprise software, and legal tech
- Robotics and automation
- Clean energy and climate technology
- Space and aerospace
- Healthcare and digital health
- Fintech and financial services
- Consumer goods and media
They maintain a dedicated Life Science Department that invests exclusively in biopharmaceuticals and regenerative medicine, staffed by consultants with deep domain expertise. MUCAP also works closely with leading universities, actively investing in university spin-offs.
Stage Focus
MUCAP is explicitly stage-agnostic. They back companies from Pre-Seed and Seed through later stages (Series C, D, E+), and maintain post-IPO positions as well. Their stated approach is to support start-ups "from the seed / early stage, through the middle stage, to the later stage where an initial public offering (IPO) or M&A comes into view." The firm has invested in companies at every stage from pre-seed through Series G (CureApp).
Check Size
Investment ticket typically ranges from $10M to $50M per Private Equity International, though early-stage checks can be as small as $500K-$1M for seed rounds. The firm's average deal size across its portfolio is approximately $3.56M, reflecting the breadth from small seed to large later-stage rounds. The most recent fund (Main Fund, December 2023) focuses on Pre-seed through Series A.
Lead Tendency
MUCAP typically participates in syndicated rounds alongside other Japanese VCs and corporate investors. They are frequently a co-investor with Mizuho Capital, SMBC Venture Capital, Sparx Asset Management, and University of Tokyo Edge Capital Partners (UTEC). They may lead smaller rounds, particularly in life sciences where they have dedicated expertise.
Recent Activity
Since becoming Mitsubishi UFJ Capital in fiscal 2005, the firm has made approximately 1,914 investments with an aggregate value of approximately ¥116 billion (as of March 2026). This represents some of the most prolific VC activity in Japan. In FY2025 alone, the firm made approximately 200 new investments — their highest single-year total in recent history. As of May 2026, they made 43 new investments in the prior 12 months.
Notable recent portfolio entries (2025-2026) include:
- TriOrb (Series B, June 2026) — 360° omnidirectional mobility platform for factories
- dodoAI (Seed, June 2026) — Sovereign Agentic OS for enterprise AI governance
- ATOM Inc. / Atom Humanoid (Seed, June 2026) — humanoid robot platform
- SIGQ Co., Ltd. (June 2026) — new investment
- Neusignal Therapeutics (Series B, June 2026) — therapeutics for dementia and psychiatric illness ($32.8M)
- ElevationSpace (Series B, June 2026) — satellite manufacturing and in-orbit space environment utilization ($39.7M)
- LegalOn Technologies (Series E, July 2025) — legal AI platform ($50M round)
- KAKEHASHI (Series D, June 2025) — medical technology ($96.7M round)
- Fermelanta (Series A, August 2025) — rare plant-based ingredients via microbial fermentation ($13.6M)
Portfolio Highlights
More than 870 companies backed by MUCAP have gone public through IPO — an extraordinary track record in Japan's venture ecosystem. Notable portfolio companies include:
- CureApp — digital therapeutics / medical device software for smoking cessation and other conditions; raised through Series G ($52M)
- LegalOn Technologies — enterprise legal AI, one of Japan's largest legal tech companies
- KAKEHASHI — healthcare SaaS, one of Japan's largest health tech companies
- WHILL — intelligent personal electric vehicle company (listed)
- AnyMind Group — commerce enablement and marketing technology (listed in Singapore)
- Astroscale — space debris removal and on-orbit services (listed)
- Techtouch — digital adoption platform, Series C ($27.9M)
- Taranis — crop intelligence and precision agriculture (US-based, Series D $40M)
Team
- Hiroyuki Hasegawa — Executive Officer and Head of Life Science Department; leads the specialized life science investment practice
- Ryota Kakinuma — Capitalist
- Takuro Kojima — Capitalist
- Yukihiro Shiraishi — Capitalist
- Takashige Kuki — Capitalist
- Akihiro Fukushima — Capitalist
- Yoshimitsu Tamura — Deputy General Manager
The firm has 51-200 employees (LinkedIn) and capitalizes its investing through a team-based approach: each investee has a dedicated team consisting of a capitalist (investment professional), a business strategy partner with extensive industrial expertise, and partnership development staff who forge relationships with large companies.
Capitalists are stationed at the Tokyo headquarters (Nihonbashi, Chuo-ku) as well as regional offices in Osaka and Nagoya, enabling closer collaboration with startups across Japan.
Decision Process
Given the firm's institutional structure as part of MUFG and their team-based investment approach, investment decisions are made through an investment committee. The team approach — capitalist + business strategy partner + partnership staff — suggests a multi-stakeholder process before capital deployment.
Founder Preferences
MUCAP backs entrepreneurs across all domains, with particular affinity for:
- University spin-offs and deep science commercialization
- Founders in life sciences, biotech, and new industrial fields where commercialization timelines are long
- Japanese startups with global ambitions (they offer the MUFG worldwide network as a "Bridge to Global Market")
- Teams seeking not just capital but operational partnership (business development, organizational guidance, MUFG banking relationships)
Geographic Focus
Primarily Japan, with offices in Tokyo, Osaka, and Nagoya. Selective international investments in Asia (Singapore via AnyMind Group) and North America (Taranis, Alviere). MUFG's global presence enables portfolio companies to expand internationally.
Track Record
Founded in 1974, MUCAP is one of Japan's oldest and most prolific venture capital firms. 870+ portfolio companies have gone public. The firm celebrated its 50th anniversary in 2024. Total investment since fiscal 2005: ~1,914 deals, ¥116 billion aggregate value. The firm invests from its own balance sheet through MUFG backing, providing patient capital that complements traditional LP-funded VCs.